Organogenesis (NASDAQ:ORGO) Downgraded to “Hold” Rating by Wall Street Zen

Wall Street Zen downgraded shares of Organogenesis (NASDAQ:ORGO) from a strong-buy rating to a hold rating in a report published on Saturday morning.

Other equities research analysts have also issued reports about the stock. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Organogenesis in a research note on Monday, December 29th. BTIG Research dropped their target price on shares of Organogenesis from $9.00 to $8.00 and set a “buy” rating on the stock in a report on Friday. Two equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, Organogenesis has a consensus rating of “Moderate Buy” and a consensus price target of $7.67.

Organogenesis Price Performance

Shares of ORGO opened at $3.21 on Friday. Organogenesis has a 1 year low of $2.61 and a 1 year high of $7.08. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.32 and a quick ratio of 2.88. The company has a market capitalization of $407.38 million, a price-to-earnings ratio of 40.13 and a beta of 1.46. The business has a 50-day moving average of $4.23 and a 200-day moving average of $4.58.

Organogenesis (NASDAQ:ORGO) last announced its earnings results on Thursday, February 26th. The company reported $0.31 EPS for the quarter, beating the consensus estimate of $0.21 by $0.10. The business had revenue of $225.61 million for the quarter, compared to analysts’ expectations of $172.68 million. Organogenesis had a return on equity of 22.64% and a net margin of 5.32%. As a group, equities research analysts anticipate that Organogenesis will post -0.07 earnings per share for the current year.

Insider Activity

In other news, Director Glenn H. Nussdorf sold 200,000 shares of the stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $5.14, for a total transaction of $1,028,000.00. Following the transaction, the director owned 2,565,591 shares of the company’s stock, valued at $13,187,137.74. This represents a 7.23% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 33.00% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in ORGO. Strs Ohio acquired a new stake in Organogenesis in the first quarter valued at approximately $105,000. Acadian Asset Management LLC lifted its holdings in shares of Organogenesis by 3.9% in the 2nd quarter. Acadian Asset Management LLC now owns 2,424,363 shares of the company’s stock worth $8,862,000 after purchasing an additional 91,118 shares in the last quarter. Creative Planning lifted its holdings in shares of Organogenesis by 84.5% in the 2nd quarter. Creative Planning now owns 35,392 shares of the company’s stock worth $130,000 after purchasing an additional 16,205 shares in the last quarter. Cetera Investment Advisers acquired a new stake in Organogenesis in the 2nd quarter valued at $222,000. Finally, Catalyst Funds Management Pty Ltd bought a new stake in Organogenesis during the 2nd quarter valued at $63,000. 49.57% of the stock is owned by institutional investors and hedge funds.

More Organogenesis News

Here are the key news stories impacting Organogenesis this week:

• Positive Sentiment: Record Q4 results — Organogenesis reported Q4 revenue of $225.6M (big beat) and EPS that topped estimates, with strong gross‑profit and operating‑profit expansion and materially higher operating cash flow. This explains recent upside in sentiment from the quarter’s beat. Organogenesis Reports Fourth Quarter 2025 Financial Results
• Neutral Sentiment: Analyst price‑target adjustment — BTIG trimmed its target from $9.00 to $8.00 but maintained a Buy rating, still implying substantial upside from today’s price. This keeps some analyst support but signals more cautious optimism. BTIG Price Target Update via Benzinga
• Negative Sentiment: Weak FY‑2026 guidance — management issued revenue guidance of $350M–$420M for FY‑2026, well below consensus (~$543M). The large gap between the outlook and street expectations is the primary driver of the stock weakening today. FY‑2026 Guidance and Earnings Release (MarketBeat)
• Negative Sentiment: Insider and institutional flows — notable insider selling (reported large insider sales) and mixed institutional activity (some large redemptions/position cuts) may add selling pressure or indicate some investors are booking gains after the strong quarter. QuiverQuant Coverage of Q4 Results & Insider Activity

Organogenesis Company Profile

Organogenesis Inc operates as a regenerative medicine company focused on the development, manufacturing and commercialization of therapeutic solutions for wound care, surgical repair and sports medicine. The company’s product portfolio addresses a range of acute and chronic tissue repair needs, leveraging bioengineered skin substitutes, human placental-derived products and other allografts designed to promote healing and reduce scarring. Organogenesis markets its therapies to hospitals, outpatient clinics, wound care centers and other healthcare providers.

Key offerings include Apligraf, a living skin substitute for treatment of diabetic foot ulcers and venous leg ulcers; Dermagraft, a cryopreserved human fibroblast-derived dermal substitute; Grafix, a placental membrane allograft for complex and chronic wounds; and TheraSkin, a cryopreserved human skin allograft used in surgical and reconstructive procedures.